Efficacy of decitabine in advanced chronic myelomonocytic leukemia (CMML) patients

被引：0

作者：

Santini, V. ^{[1
]}

Allione, B. ^{[2
]}

Lunghi, M. ^{[3
]}

Levis, A. ^{[4
]}

Poloni, A. ^{[5
]}

Angelucci, E. ^{[6
]}

Onida, F. ^{[7
,8
]}

Terenzi, A. ^{[9
]}

Finelli, C. ^{[10
]}

Ferrero, D. ^{[2
]}

机构：

[1] AOU Careggi Univ Florence, Hematol, Florence, Italy

[2] Univ Turin, San Giovanni Battista Hosp, Hematol, Turin, Italy

[3] Amedeo Avogadro Univ Eastern Piedmont, Dept Translat Med, Hematol, Novara, Italy

[4] Osped SSAntonio & Biagio, Hematol, Alesssandria, Italy

[5] Univ Ancona Hosp, Hematol, Ancona, Italy

[6] Osped Oncol Armando Businco, Hematol, Cagliari, Italy

[7] IRCCS Fdn Ca Granda, Hematol, Milan, Italy

[8] Univ Milan, Milan, Italy

[9] AO Silvestrini, Oncol & Hematol, Perugia, Italy

[10] Osped S Orsola Malpighi, Ist Seragnoli Hematol, Bologna, Italy

来源：

LEUKEMIA RESEARCH | 2013年 / 37卷

关键词：

D O I：

10.1016/S0145-2126(13)70040-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

O-018

引用

页码：S17 / S17

页数：1

共 50 条

[21] Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale
Ramadan, Hanadi
Duong, Vu H.
Al Ali, Najla
Padron, Eric
Zhang, Ling
Lancet, Jeffrey E.
List, Alan F.
Komrokji, Rami S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 : S64 - S66
[22] Clinical Outcomes of Oligomonocytic Chronic Myelomonocytic Leukemia (OM-CMML) and Predictive Factors of Evolution of OM-CMML into Overt Chronic Myelomonocytic Leukemia (CMML)
Roman-Bravo, David
Arenillas, Leonor
Asensi, Maria Teresa
Garcia-Gisbert, Nieves
Rodriguez-Sevilla, Juan Jose
Merchan, Brayan
Avila, Sara Garcia
Bellosillo, Beatriz
Fernandez-Rodriguez, Concepcion
Florensa, Lourdes
Ferrer, Ana
Calvo, Xavier
BLOOD, 2021, 138
[23] Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents
Venugopal, Sangeetha
Chien, Kelly S.
Hammond, Danielle
Kanagal-Shamanna, Rashmi
Sasaki, Koji
Kadia, Tapan M.
DiNardo, Courtney D.
Konopleva, Marina
Daver, Naval
Ravandi, Farhad
Pemmaraju, Naveen
Short, Nicholas J.
Issa, Ghayas C.
Takahashi, Koichi
Estrov, Zeev E.
Pierce, Sherry A.
Kantarjian, Hagop
Garcia-Manero, Guillermo
Montalban-Bravo, Guillermo
BLOOD, 2021, 138
[24] Comorbid conditions and transplant success in patients with chronic myelomonocytic leukemia (CMML)
Kerbauy, DMB
Chyou, F
Gooley, T
Sorror, ML
Scott, B
Pagel, JM
Myerson, D
Appelbaum, FR
Storb, R
Deeg, HJ
EXPERIMENTAL HEMATOLOGY, 2005, 33 (07) : 127 - 128
[25] Autoimmunity in Patients (pts) with Chronic Myelomonocytic Leukemia (CMML): A Frequent Finding
Swedeh, Amer
Patnaik, Mrinal
Alfakara, Dima
Ashrani, Aneel A.
Pruthi, Rajiv
Elliott, Michelle
Litzow, Mark
Al-Kali, Aref
BLOOD, 2012, 120 (21)
[26] Eltrombopag Use in Chronic Myelomonocytic Leukemia (CMML) Patients: A Cautionary Tale
Ramadan, Hanadi
Duong, Vu H.
Al Ali, Najla H.
Padron, Eric
Zhang, Ling
Lancet, Jeffrey E.
List, Alan F.
Komrokji, Rarni S.
BLOOD, 2015, 126 (23)
[27] PROGNOSTIC FACTORS IN ADULT CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
FENAUX, P
BEUSCART, R
JOUET, JP
BAUTERS, F
BLUT, 1988, 56 (06): : C12 - C12
[28] A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1
Burgstaller, Sonja
Stauder, Reinhard
Kuehr, Thomas
Lang, Alois
Machherndl-Spandl, Sigrid
Mayrbaeurl, Beate
Noesslinger, Thomas
Petzer, Andreas
Valent, Peter
Greil, Richard
Thaler, Josef
LEUKEMIA & LYMPHOMA, 2018, 59 (05) : 1121 - 1126
[29] PROGNOSTIC FACTORS AND SURVIVAL IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
STARK, AN
THOROGOOD, J
HEAD, C
ROBERTS, BE
SCOTT, CS
BRITISH JOURNAL OF CANCER, 1987, 56 (01) : 59 - 63
[30] CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) - A MYELODYSPLASTIC OR MYELOPROLIFERATIVE SYNDROME
MICHAUX, JL
MARTIAT, P
LEUKEMIA & LYMPHOMA, 1993, 9 (1-2) : 35 - 41

← 1 2 3 4 5 →